StreetInsider.com News Articles

Earnings dip in this chip stock creates buying opportunity ahead of Investor Day: analyst

Thu, 03 Sep 2026 19:00:00 -0400

Investing.com -- Investors could use any weakness in a semiconductor stock following its latest earnings report as a buying opportunity ahead of an analyst day in early October, according to Rosenblatt Securities, which said accelerating data-center growth supports the company’s longer-term outlook.

Rosenblatt said growth is broadening across interconnect, switching, custom silicon and scale-up connectivity. Management raised its fiscal 2027 and fiscal 2028 revenue outlooks by $500 million and $1.5 billion, respectively, to about $12 billion and $18 billion, representing increases of 4% and 9% from its previous forecasts. Higher operating expenses and M&A-related dilution, however, limited the broker’s corresponding EPS

Earnings dip in this chip stock creates buying opportunity ahead of Investor Day: analyst

Thu, 03 Sep 2026 19:00:00 -0400

Marvel Biosciences Announces Grant of Deferred Share Units

Tue, 01 Sep 2026 17:01:00 -0400

Calgary, Alberta--(Newsfile Corp. - September 1, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 50,001 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees.

The DSUs will all vest on September 1, 2027. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days after such directors' separation from service.

The deemed value for the DSUs is calculated using the VWAP of the Corporation's Common Shares on the TSX Venture

Marvel Biosciences Announces Grant of Deferred Share Units

Tue, 01 Sep 2026 17:01:00 -0400

The deemed value for the DSUs is calculated using the VWAP of the Corporation's Common Shares on the TSX Venture

Form 10-Q Marvell Technology, Inc. For: Aug 01

Fri, 28 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260828/26997808.html

Form 10-Q Marvell Technology, Inc. For: Aug 01

Fri, 28 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260828/26997808.html

Active options: MRVL PLTR SOFI GOOGL AMD SMCI CRM MARA HOOD

Fri, 28 Aug 2026 14:51:24 -0400

Active options: MRVL PLTR SOFI GOOGL AMD SMCI CRM MARA HOOD

Marvell (MRVL) PT Raised to $325 at Oppenheimer

Fri, 28 Aug 2026 13:34:22 -0400

(Updated - August 28, 2026 1:34 PM EDT)

Oppenheimer analyst Rick Shafer raised the price target on Marvell (NASDAQ: MRVL) to $325.00 (from $300.00) while maintaining a Outperform rating.

The analyst commented: "MRVL reported upside F2Q (July) results and F3Q (Oct.) outlook Thursday, led by DCAI. Mgmt. again raised CY26 top-line outlook. Now $12B (up from $11.5B last Q and $9.5B provided in Sept. ’25). CY27 top line now expected $18B (vs. $16.5B outlook in May, $15B in March). Bulk of raise driven by interconnect with additional upside from custom. Custom tracking north
of $2B this year, expected to more than double

Marvell (MRVL) PT Raised to $325 at Oppenheimer

Fri, 28 Aug 2026 13:34:22 -0400

(Updated - August 28, 2026 1:34 PM EDT)

Oppenheimer analyst Rick Shafer raised the price target on Marvell (NASDAQ: MRVL) to $325.00 (from $300.00) while maintaining a Outperform rating.

Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak